Join our daily newsletter At The Bell to receive exclusive market insights
- Lumos Diagnostics (LDX) inks an agreement with Henry Schein Medical, S.L.U. for its FebriDx point-of-care (POC) test to expand into Spain and Portugal markets
- FebriDx is a rapid POC test used to differentiate viral infections from bacterial acute respiratory infections
- Henry Schein’s in Spain is part of US-listed Henry Schein (Nasdaq: HSIC), the largest global provider of healthcare solutions to dental and medical practitioners
- Chief Executive Officer Doug Ward states the company is altering production rates of FebriDx to meet the anticipated growing demand for the product
- LDX shares were up 15.58% at 10:55 am AEST trading at 8.9 cents on Tuesday
Lumos Diagnostics (LDX) has signed an agreement with Henry Schein Medical, S.L.U. for its FebriDx point-of-care (POC) test.
FebriDx is a rapid POC test used to differentiate viral infections from bacterial acute respiratory infections, and the agreement expands Henry Schein’s distribution of FebriDx to include Spain and Portugal.
FebriDx delivers results in 10 minutes from fingerstick blood to help rapidly manage infectious patients in primary care, urgent care, emergency, paediatric and other outpatient settings.
Henry Schein’s Medical business in Spain is part of Henry Schein (Nasdaq: HSIC), the world’s largest provider of healthcare solutions for dental and medical practitioners.
Henry Schein will sell the FebriDx test throughout Spain and Portugal with sales and marketing activities commencing immediately.
“It is great to see the increased interest in our FebriDx test from one of the world’s largest distributors of healthcare and medical products,” LDX Chief Executive Officer Doug Ward said.
“Henry Schein has been a terrific and supportive partner for Lumos in the UK, despite the headwinds the pandemic generated for products such as FebriDx.
“With our recent US clearance and the growing commercial interest in FebriDx, we are now preparing production of FebriDx to meet the anticipated growing demand for the product, and further refining our US and global sales strategy.”
LDX shares were up 15.58% at 10:55 am AEST trading at 8.9 cents on Tuesday.
